

# Epithelial to Mesenchymal Transition Confers Sensitivity to Cytotoxic Agent Ophiobolin A via Alterations in Mitochondrial Function and Metabolic Pathways



Haleigh Parker<sup>1</sup>, Alexander Kornienko<sup>2</sup>, Antonio Evidente<sup>3</sup>, Daniel Romo<sup>4</sup>, Benny Abraham Kaiparettu<sup>5,6</sup>, Joseph Taube<sup>1,6</sup>

1. Department of Biology, Baylor University, Waco, TX, USA 2. Department Chemistry and Biochemistry, Texas State University, San Marcos, TX, USA 3. Department of Chemical Sciences, University of Naples Federico II, Complesso Universitario Monte Sant'Angelo, Naples, Italy 4. Department of Chemistry and Biochemistry, Baylor University, Waco, TX, USA 5. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA 6. Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA


## ABSTRACT

Metastatic progression in patients with triple negative breast cancer (TNBC) occurs in approximately half of all patients, reducing median overall survival. Metastasis may be facilitated through the epithelial to mesenchymal transition (EMT), which generates cancer cells with enhanced self-renewal and resistance to chemotherapeutics, which are partially mediated by alterations in metabolic pathways and mitochondrial function. Here we show that a drug-like small molecule possesses EMT-specific cytotoxic activity through effects on metabolic and mitochondrial functions. The fungus-derived sesterterpenoid, Ophiobolin A (OpA), possesses nanomolar cytotoxic activity and a high therapeutic index, though its target and mechanism of action remain unknown. Our analysis indicates that OpA acts in a mitochondria-specific manner to cause a loss of membrane potential in EMT-positive, but not EMT-negative, cells with specific effects on complex III of the electron transport chain, mitochondrial DNA copy number, and the TCA cycle. Therefore, we conclude that EMT imparts alterations in mitochondrial function and metabolic pathways, conferring sensitivity to the cytotoxic effects of OpA.

## CONCLUSIONS

- OpA decreases mitochondrial DNA copy number and dose dependently decreases the activity of complexes II & III in MDA-MB-231 cells.
- Placing a mitochondria from a cancerous cell into a non-cancerous cell confers enhanced OpA sensitivity. Likewise, placing a mitochondria from a healthy cell into a cancerous cell results in decreased OpA sensitivity.
- OpA induces a loss in membrane potential and a shift toward non-functional mitochondria.
- OpA significantly deregulates specific metabolites involved in glycolysis, TCA cycle and the glutamine pathway.

## RESULTS



## ACKNOWLEDGEMENTS

I would like to thank everyone in the Taube Lab; my research committee: Dr. Panos Koutakis, Dr. Bessie Kebaara, Dr. Daniel Romo and Dr. Leigh Greathouse; the researchers at the Baylor College of Medicine Metabolomics Core; Dr. Gloria Echeverria at BCM; Dr. Keighley Reisenauer; and my husband.